Galera Therapeutics, Inc.
GRTX
$0.0235
-$0.0004-1.67%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -50.71% | 23.75% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -56.65% | -11.05% | |||
| Operating Income | 56.65% | 11.05% | |||
| Income Before Tax | 14.75% | -42.32% | |||
| Income Tax Expenses | 100.00% | -- | |||
| Earnings from Continuing Operations | 11.65% | -37.33% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 11.65% | -37.33% | |||
| EBIT | 56.65% | 11.05% | |||
| EBITDA | 56.59% | 11.04% | |||
| EPS Basic | 13.16% | -37.35% | |||
| Normalized Basic EPS | 70.43% | 10.92% | |||
| EPS Diluted | 13.16% | -37.35% | |||
| Normalized Diluted EPS | 70.43% | 10.92% | |||
| Average Basic Shares Outstanding | 1.77% | 0.00% | |||
| Average Diluted Shares Outstanding | 1.77% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||